Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814892 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00814892: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00814892 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00814892, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer. PURPOSE: This phase II trial is studying how well the combination of a proven effective allogenic whole prostate carcinoma cell (APCC) vaccine co-administered with ex vivo generated dendritic cells (DCs)(DC-APCC) extend the time to prostate cancer progression.
Interventions
- BIOLOGICAL allogeneic tumor cell vaccine
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814892
The ClinicalTrials.gov registry entry for NCT00814892 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which allogeneic tumor cell vaccine is the first listed.
NCT00814892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814892 about?
NCT00814892 is a clinical study titled "Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer". RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer. PURPOSE: This phase II trial is studying how well the combination of ...
What is the current status of trial NCT00814892?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00814892?
The interventions under investigation include: allogeneic tumor cell vaccine (BIOLOGICAL), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00814892?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.